Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer's Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease

Full dataset on 140 patients in mild, moderate and severe Alzheimer’s disease subjects expected to be announced in December 2014 SAN FRANCISCO and GENEVA, Nov. 20, 2014 (GLOBE NEWSWIRE) — Amarantus B…Read More »

Amarantus passe un accord d’option exclusive pour l’acquisition auprès de Lonza d’un substitut de peau artificielle pour le traitement des brûlures graves

Substitut de peau artificielle (ESS : Engineered Skin substitute) : Candidat produit de phase I/phase II précoce ayant le potentiel de devenir un nouveau traitement révolutionnaire des brûlures graves…Read More »

Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza

Engineered Skin substitute (ESS): Phase 1/ Early Phase 2 product candidate that has potential to be a revolutionary new treatment for severe burns ESS granted Orphan Drug designation and, upon exercis…Read More »

Amarantus unterzeichnet exklusive Optionsvereinbarung zum Erwerb eines gezüchteten Hautersatzes (Engineered Skin Substitute) zur Behandlung schwerer Verbrennungen von Lonza

Hautersatz „Engineered Skin Substitute“ (ESS): Produktkandidat in der Phase 1/ frühen Phase 2 mit dem Potenzial einer revolutionären neuen Behandlung schwerer Verbrennungen Orphan-Drug-Status für ESS…Read More »

Amarantus to Host Business Update Conference Call on November 18, 2014

Conference Call and Webcast Scheduled for Tuesday at 8 a.m. EST SAN FRANCISCO and GENEVA, Switzerland, Nov. 17, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a diversified…Read More »
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).

Company Information

Company Website: http://www.amarantus.com/
Company Headquarters

c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107
Phone: (408) 737-2734
Fax: (408) 852-4427
info@amarantus.com

Media and Investor Relations Contact

Aimee Boutcher, Director of Investor Relations
Phone: (408) 737-2734 x 101
ir@amarantus.com

Forward Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

This Blog is official and sanctioned by Amarantus BioScience | See Disclaimer | See Privacy Policy

Get Amarantus BioScience Blog Post Alerts